Who owns CYTOKINETICS INC (CYT)? Elite investor 13F holders
5 tracked elite investors reported holding CYTOKINETICS INC as of 2026-06-30, including D.E. Shaw, Sarissa Capital, Tudor Investment, Gotham Asset Management, GAMCO. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel,…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | CYTOKINETICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 89287894.00 USD | 1048103.000000 | Shares | add | Original filing |
| Sarissa Capital | CYTOKINETICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 19476393.00 USD | 228623.000000 | Shares | hold | Original filing |
| Tudor Investment | CYTOKINETICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 7895409.00 USD | 92680.000000 | Shares | buy | Original filing |
| Gotham Asset Management | CYTOKINETICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 457215.00 USD | 5367.000000 | Shares | buy | Original filing |
| GAMCO | CYTOKINETICS INC | SHARE | 2026-06-30 | 2026-08-12 00:00:00 | 341026.00 USD | 200000.000000 | Principal | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.